数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Kristin C. Peck Chief Executive Officer and Director 52 1523.79万美元 8.02 2024-04-16
Antoinette R. Leatherberry Director 62 34.00万美元 0.22 2024-04-16
Gavin D.K. Hattersley Director 61 未披露 0.08 2024-04-16
Robert W. Scully Director 74 36.50万美元 1.97 2024-04-16
Frank A. D'Amelio Director 66 34.05万美元 1.48 2024-04-16
Michael B. McCallister Chairman and Director 71 49.00万美元 2.59 2024-04-16
Gregory Norden Director 66 36.50万美元 1.51 2024-04-16
Paul M. Bisaro Director 63 34.00万美元 2.18 2024-04-16
Sanjay Khosla Director 72 34.00万美元 0.98 2024-04-16
Louise M. Parent Director 73 37.00万美元 1.37 2024-04-16
Willie M. Reed Director 69 37.00万美元 1.00 2024-04-16
Vanessa Broadhurst Director 55 34.10万美元 0.10 2024-04-16

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Kristin C. Peck Chief Executive Officer and Director 52 1523.79万美元 8.02 2024-04-16
Wetteny Joseph Executive Vice President and Chief Financial Officer 52 424.78万美元 0.09 2024-04-16
Wafaa Mamilli Executive Vice President, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health 57 268.65万美元 0.67 2024-04-16
Jeannette Ferran Astorga Executive Vice President, Corporate Affairs, Communications and Chief Sustainability Officer 49 未披露 未持股 2024-04-16
Robert J. Polzer -- Executive Vice President and President, Research and Development 55 244.05万美元 0.43 2024-04-16
Nick Ashton Executive Vice President and President, Global Manufacturing and Supply 51 未披露 未持股 2024-04-16
Jamie Brannan Executive Vice President and Group President International Operations, Aquaculture and Global Diagnostics 51 未披露 未持股 2024-04-16
Rimma Driscoll Executive Vice President and Head of Global Strategy, Commercial and Business Development and Global BioDevices 51 未披露 未持股 2024-04-16
Ester Banque Executive Vice President and President, U.S. Operations 54 未披露 未持股 2024-04-16
Roxanne Lagano Executive Vice President, Chief Human Resources Officer and Global Operations,interim General Counsel and Corporate Secretary 59 未披露 未持股 2024-04-16

董事简历

中英对照 |  中文 |  英文
Kristin C. Peck

Kristin C. Peck,自2020年1月起担任Zoetis公司首席执行官,自2019年10月起担任董事。在担任首席执行官之前,Peck女士于2018年3月至2019年12月在Zoetis担任执行副总裁兼集团总裁,负责美国业务、业务发展和战略。Peck女士曾于2015年5月至2018年2月担任Zoetis公司执行副总裁兼美国业务总裁,并于2012年10月至2015年4月担任执行副总裁兼集团总裁。在担任这些职务期间,Peck女士帮助Zoetis Inc.完成了Zoetis在2013年的首次公开发行,并推动了全球制造和供应、全球家禽、全球诊断、企业发展、新产品营销和全球市场研究等领域的变革。Peck女士于2004年加入Pfizer,担任过多个职位,包括全球业务发展和创新执行副总裁,以及Pfizer执行领导团队的成员。


Kristin C. Peck,currently serves as Zoetis' Chief Executive Officer, a role she has held since January 2020, and as member of the Board of Directors since October 2019. Prior to becoming CEO at Zoetis, the global leader in the animal health industry, Ms. Peck was Executive Vice President and Group President, U.S. Operations, Business Development and Strategy at Zoetis from March 2018 to December 2019. Ms. Peck previously served as Zoetis Inc. Executive Vice President and President, U.S. Operations from May 2015 to February 2018 and Executive Vice President and Group President from October 2012 through April 2015, where she had oversight for Zoetis Inc. business development, global manufacturing and supply and marketing and sales functions. In these roles, Ms. Peck helped Zoetis Inc. her Zoetis through its Initial Public Offering in 2013 and has been a driving force of change in areas including Global Manufacturing and Supply, Global Poultry, Global Diagnostics, Corporate Development, and New Product Marketing and Global Market Research. Before joining Zoetis, Ms. Peck served as Executive Vice President, Worldwide Business Development and Innovation at Pfizer Inc. (February 2004 - October 2012) and as a member of Pfizer's Executive Leadership Team, where she gained human capital management experience. Prior to joining Pfizer, Ms. Peck held roles at The Boston Consulting Group (BCG) (1999 - 2004) as well as in private equity and real estate finance at The Prudential Realty Group, The O'Connor Group and J.P. Morgan.In addition to her service on the Zoetis Board of Directors, Ms. Peck currently serves as a member of the Board of Directors of BlackRock (since September 2021), the Board of Trustees of Mayo Clinic and of the Board of Directors of Catalyst, a global non-profit that helps companies accelerate women into leadership, and she formerly served on the Board of Directors of Thomson Reuters. Ms. Peck is a member of the Business Roundtable, The Business Council and is also a member of the Columbia Business School Board of Directors. Ms. Peck holds a bachelor's degree from Georgetown University and an MBA from Columbia Business School. Ms. Peck's knowledge and leadership of the Company as Zoetis Inc. current CEO, her animal health and pharmaceutical industry experience, and her global operational expertise, along with her public company board experience, make her a valuable member of Zoetis Inc. Board.
Kristin C. Peck,自2020年1月起担任Zoetis公司首席执行官,自2019年10月起担任董事。在担任首席执行官之前,Peck女士于2018年3月至2019年12月在Zoetis担任执行副总裁兼集团总裁,负责美国业务、业务发展和战略。Peck女士曾于2015年5月至2018年2月担任Zoetis公司执行副总裁兼美国业务总裁,并于2012年10月至2015年4月担任执行副总裁兼集团总裁。在担任这些职务期间,Peck女士帮助Zoetis Inc.完成了Zoetis在2013年的首次公开发行,并推动了全球制造和供应、全球家禽、全球诊断、企业发展、新产品营销和全球市场研究等领域的变革。Peck女士于2004年加入Pfizer,担任过多个职位,包括全球业务发展和创新执行副总裁,以及Pfizer执行领导团队的成员。
Kristin C. Peck,currently serves as Zoetis' Chief Executive Officer, a role she has held since January 2020, and as member of the Board of Directors since October 2019. Prior to becoming CEO at Zoetis, the global leader in the animal health industry, Ms. Peck was Executive Vice President and Group President, U.S. Operations, Business Development and Strategy at Zoetis from March 2018 to December 2019. Ms. Peck previously served as Zoetis Inc. Executive Vice President and President, U.S. Operations from May 2015 to February 2018 and Executive Vice President and Group President from October 2012 through April 2015, where she had oversight for Zoetis Inc. business development, global manufacturing and supply and marketing and sales functions. In these roles, Ms. Peck helped Zoetis Inc. her Zoetis through its Initial Public Offering in 2013 and has been a driving force of change in areas including Global Manufacturing and Supply, Global Poultry, Global Diagnostics, Corporate Development, and New Product Marketing and Global Market Research. Before joining Zoetis, Ms. Peck served as Executive Vice President, Worldwide Business Development and Innovation at Pfizer Inc. (February 2004 - October 2012) and as a member of Pfizer's Executive Leadership Team, where she gained human capital management experience. Prior to joining Pfizer, Ms. Peck held roles at The Boston Consulting Group (BCG) (1999 - 2004) as well as in private equity and real estate finance at The Prudential Realty Group, The O'Connor Group and J.P. Morgan.In addition to her service on the Zoetis Board of Directors, Ms. Peck currently serves as a member of the Board of Directors of BlackRock (since September 2021), the Board of Trustees of Mayo Clinic and of the Board of Directors of Catalyst, a global non-profit that helps companies accelerate women into leadership, and she formerly served on the Board of Directors of Thomson Reuters. Ms. Peck is a member of the Business Roundtable, The Business Council and is also a member of the Columbia Business School Board of Directors. Ms. Peck holds a bachelor's degree from Georgetown University and an MBA from Columbia Business School. Ms. Peck's knowledge and leadership of the Company as Zoetis Inc. current CEO, her animal health and pharmaceutical industry experience, and her global operational expertise, along with her public company board experience, make her a valuable member of Zoetis Inc. Board.
Antoinette R. Leatherberry

Antoinette R. Leatherberry,德勤会计师事务所前负责人。Leatherberry于2020年从行业领先的咨询,审计,税务和咨询服务公司Deloitte退休,此前她在复杂的信息技术转型和运营问题上与《财富》500强公司合作了30年。在德勤(Deloitte),她最近于2017年至2020年担任风险和财务咨询业务的董事会关系负责人。在2017年之前,她于2004年至2017年担任技术战略负责人。Leatherberry女士还于2016年至2020年担任德勤基金会总裁。她撰写了许多有关信息技术和治理的文章和出版物,并于2019年和2020年被任命为全国公司董事协会NACD董事职位100。Leatherberry女士在《咨询杂志》(Consulting Magazine)的25名顶级顾问和《黑人企业》(Black Enterprise)最具影响力的商界女性等出版物中获得了认可。她还将自己的大部分职业生涯奉献给了为女性和有色人种创造机会。在德勤(Deloitte),Leatherberry女士是董事会领导论坛和NextGen首席执行官学院的首席架构师,该学院帮助70多位黑人领袖进入执行级别和董事会。她担任执行领导委员会ELC的名誉主席,该委员会是黑人商业领袖的杰出协会,专注于董事会和执行领导能力发展,慈善事业,技能和人才发展。除了在Zoetis董事会任职外,Leatherberry女士还在美国家庭保险共同控股公司,Widener大学董事会和波士顿大学董事会任职。她拥有波士顿大学的机械工程学士学位和东北大学的运营管理和监督MBA学位。她目前正在维德纳大学攻读高等教育政策博士学位。


Antoinette R. Leatherberry,is a former Principal at Deloitte. Dr. Leatherberry retired from Deloitte, an industry-leading consulting, audit, tax, and advisory services company, in October 2020 after culminating a 30-year career of working with Fortune 500 companies on complex information technology transformations, strategy and implementation, data analytics, data strategy, and operational issues. At Deloitte, she most recently served as Board Relations Leader for the Risk and Financial Advisory practice from September 2017 to October 2022 and before September 2017, she served as a Principal (equity owner) in Technology Strategy since August 1991. During her tenure at Deloitte Dr. Leatherberry was responsible for leading global teams, recruiting strategies and hiring and workforce planning. Dr. Leatherberry also served as President of the Deloitte Foundation from June 2016 to October 2020. She has authored numerous articles and publications on information technology and governance and was named to the National Association of Corporate Directors (NACD) Directorship 100 in 2019 and 2020.In addition to her service on the Zoetis Board of Directors, Dr. Leatherberry currently serves as a member of the Board of Directors of Digital Direct Holdings (since February 2022). Dr. Leatherberry also sits on several private company Boards of Directors, including STRIVE (since January 2022) and the American Family Insurance Mutual Holding Company (since December 2020), the Widener University Board of Trustees, the Boston University Board of Trustees and the advisory board of the Ellig Group (since November 2022). She holds a bachelor's degree in Mechanical Engineering from Boston University, an MBA in Operations Management and Supervision from Northeastern University and recently received her EdD in education from Widener University. Dr. Leatherberry's extensive experience with complex technology transformations, her strategic digital technology experience, her corporate governance expertise, and her diversity and inclusion leadership make her a valuable member of Zoetis Inc. Board.
Antoinette R. Leatherberry,德勤会计师事务所前负责人。Leatherberry于2020年从行业领先的咨询,审计,税务和咨询服务公司Deloitte退休,此前她在复杂的信息技术转型和运营问题上与《财富》500强公司合作了30年。在德勤(Deloitte),她最近于2017年至2020年担任风险和财务咨询业务的董事会关系负责人。在2017年之前,她于2004年至2017年担任技术战略负责人。Leatherberry女士还于2016年至2020年担任德勤基金会总裁。她撰写了许多有关信息技术和治理的文章和出版物,并于2019年和2020年被任命为全国公司董事协会NACD董事职位100。Leatherberry女士在《咨询杂志》(Consulting Magazine)的25名顶级顾问和《黑人企业》(Black Enterprise)最具影响力的商界女性等出版物中获得了认可。她还将自己的大部分职业生涯奉献给了为女性和有色人种创造机会。在德勤(Deloitte),Leatherberry女士是董事会领导论坛和NextGen首席执行官学院的首席架构师,该学院帮助70多位黑人领袖进入执行级别和董事会。她担任执行领导委员会ELC的名誉主席,该委员会是黑人商业领袖的杰出协会,专注于董事会和执行领导能力发展,慈善事业,技能和人才发展。除了在Zoetis董事会任职外,Leatherberry女士还在美国家庭保险共同控股公司,Widener大学董事会和波士顿大学董事会任职。她拥有波士顿大学的机械工程学士学位和东北大学的运营管理和监督MBA学位。她目前正在维德纳大学攻读高等教育政策博士学位。
Antoinette R. Leatherberry,is a former Principal at Deloitte. Dr. Leatherberry retired from Deloitte, an industry-leading consulting, audit, tax, and advisory services company, in October 2020 after culminating a 30-year career of working with Fortune 500 companies on complex information technology transformations, strategy and implementation, data analytics, data strategy, and operational issues. At Deloitte, she most recently served as Board Relations Leader for the Risk and Financial Advisory practice from September 2017 to October 2022 and before September 2017, she served as a Principal (equity owner) in Technology Strategy since August 1991. During her tenure at Deloitte Dr. Leatherberry was responsible for leading global teams, recruiting strategies and hiring and workforce planning. Dr. Leatherberry also served as President of the Deloitte Foundation from June 2016 to October 2020. She has authored numerous articles and publications on information technology and governance and was named to the National Association of Corporate Directors (NACD) Directorship 100 in 2019 and 2020.In addition to her service on the Zoetis Board of Directors, Dr. Leatherberry currently serves as a member of the Board of Directors of Digital Direct Holdings (since February 2022). Dr. Leatherberry also sits on several private company Boards of Directors, including STRIVE (since January 2022) and the American Family Insurance Mutual Holding Company (since December 2020), the Widener University Board of Trustees, the Boston University Board of Trustees and the advisory board of the Ellig Group (since November 2022). She holds a bachelor's degree in Mechanical Engineering from Boston University, an MBA in Operations Management and Supervision from Northeastern University and recently received her EdD in education from Widener University. Dr. Leatherberry's extensive experience with complex technology transformations, her strategic digital technology experience, her corporate governance expertise, and her diversity and inclusion leadership make her a valuable member of Zoetis Inc. Board.
Gavin D.K. Hattersley

Gavin D.K. Hattersley,自2019年9月起担任摩森康胜的首席执行官。在担任现职之前,Hattersley先生曾在公司内担任多个职务,包括摩森康胜前美国分部MillerCoors的首席执行官,以及摩森康胜全球业务的首席财务官。在加入公司之前,他曾在酿酒和制造领域的国际业务中担任多个财务管理职位,包括SAB Limited和Barloworld Limited。Hattersley先生拥有南非大学会计学荣誉学位和学士学位。自2019年以来,Hattersley先生一直是摩森康胜的董事会成员,他准备为硕腾董事会带来广泛的专业知识,从企业发展和损益管理到基础广泛的财务头脑。


Gavin D.K. Hattersley,currently serves as the President and Chief Executive Officer at Molson Coors Beverage Company, a global brewing beverage company (since September 2019). Prior to his current position, Mr. Hattersley served as chief executive officer of MillerCoors, the U.S. division of Molson Coors, since September 2015. Prior to joining MillerCoors, Mr. Hattersley served as chief financial officer of Molson Coors from June 2012 to September 2015. From July 2008 to June 2012, Mr. Hattersley served as executive vice president and chief financial officer of MillerCoors. He also served as senior vice president of finance for Miller Brewing Company from October 2002 to July 2008. Prior to joining Miller Brewing Company Mr. Hattersley held several financial management positions with SAB Limited of Johannesburg, South Africa, before becoming chief financial officer in 1999. Prior to joining SAB Limited in 1997, Mr. Hattersley spent almost 10 years with Barloworld Limited in various finance positions.In addition to his service on the Zoetis Board of Directors, Mr. Hattersley currently serves as a member of the Board of Directors of Molson Coors Beverage Company. Mr. Hattersley holds an honors degree in accounting science and a bachelor's degree from the University of South Africa. Mr. Hattersley's senior management experience, including as a current chief executive officer and former chief financial officer, along with his international business and public company board experience, make him a valuable member of Zoetis Inc. Board.
Gavin D.K. Hattersley,自2019年9月起担任摩森康胜的首席执行官。在担任现职之前,Hattersley先生曾在公司内担任多个职务,包括摩森康胜前美国分部MillerCoors的首席执行官,以及摩森康胜全球业务的首席财务官。在加入公司之前,他曾在酿酒和制造领域的国际业务中担任多个财务管理职位,包括SAB Limited和Barloworld Limited。Hattersley先生拥有南非大学会计学荣誉学位和学士学位。自2019年以来,Hattersley先生一直是摩森康胜的董事会成员,他准备为硕腾董事会带来广泛的专业知识,从企业发展和损益管理到基础广泛的财务头脑。
Gavin D.K. Hattersley,currently serves as the President and Chief Executive Officer at Molson Coors Beverage Company, a global brewing beverage company (since September 2019). Prior to his current position, Mr. Hattersley served as chief executive officer of MillerCoors, the U.S. division of Molson Coors, since September 2015. Prior to joining MillerCoors, Mr. Hattersley served as chief financial officer of Molson Coors from June 2012 to September 2015. From July 2008 to June 2012, Mr. Hattersley served as executive vice president and chief financial officer of MillerCoors. He also served as senior vice president of finance for Miller Brewing Company from October 2002 to July 2008. Prior to joining Miller Brewing Company Mr. Hattersley held several financial management positions with SAB Limited of Johannesburg, South Africa, before becoming chief financial officer in 1999. Prior to joining SAB Limited in 1997, Mr. Hattersley spent almost 10 years with Barloworld Limited in various finance positions.In addition to his service on the Zoetis Board of Directors, Mr. Hattersley currently serves as a member of the Board of Directors of Molson Coors Beverage Company. Mr. Hattersley holds an honors degree in accounting science and a bachelor's degree from the University of South Africa. Mr. Hattersley's senior management experience, including as a current chief executive officer and former chief financial officer, along with his international business and public company board experience, make him a valuable member of Zoetis Inc. Board.
Robert W. Scully

Robert W. Scully,2010年7月15日起,担任本公司管理合伙人的董事。2007年直到2009年退休,他是Morgan Stanley董事长的办公室成员;之前,他曾担任该公司的全球资本市场部联席总裁与主席、投资银行部副主席。加入Morgan Stanley之前,他曾担任Lehman Brothers 和 Salomon Brothers的总经理。2013年6月起,他是Zoetis的董事。之前,他曾担任Bank of America Corporation的董事,直到2013年5月,也曾担任GMAC Financial Services 和 MSCI Inc.的董事。他获得了Princeton University的学士学位、Harvard Business School的工商管理硕士学位。他在金融服务行业有着35年的丰富经验,为本公司的监管带来了重要的专业知识。另外,他在全球性金融服务 公司的领导任职经验,也为本公司在美国和国际上的许多事务带来了行业性的视角,比如业务开发、人才开发、高级客户关系管理、战略行动、风险管理、审核与财务报告。


Robert W. Scully,is a former member of the Office of the Chairman of Morgan Stanley, a role in which he served from 2007 until January 2009. Prior to his service as a member of the Office of the Chairman of Morgan Stanley, he served as Co-President responsible for Asset Management, Discover Credit Cards from 2006 to 2007, where several global business units reported directly to him, and he was responsible for marketing and sales. Prior to assuming the position of Co-President at Morgan Stanley, he served as Chairman of Global Capital Markets from 2004 to 2006, Vice Chairman of Investment Banking from 1999 to 2006, and Managing Director from 1996 to 2009, where he gained human capital management experience. Prior to joining Morgan Stanley in 1996, Mr. Scully served as Managing Director at Lehman Brothers from 1993 to 1996, as Managing Director at Scully Brothers Foss & Wight from 1989 to 1993 and as Managing Director at Salomon Brothers in Investment Banking and Capital Markets from 1984 to 1989. Mr. Scully has over 30 years of leadership experience in the global financial services industry, particularly in providing strategic advice to global enterprises regarding M&A transactions.In addition to his service on the Zoetis Board of Directors, Mr. Scully currently serves as a member of the Board of Directors of KKR & Co. Inc. (since July 2010) and Chubb Limited (since May 2014). Previously, he served as a member of the Boards of Directors of UBS Group AG, Bank of America Corporation, GMAC Financial Services and MSCI Inc., and as a Public Governor of FINRA, Inc., the Financial Industry Regulatory Authority. Mr. Scully holds a bachelor's degree from Princeton University and an MBA from Harvard Business School, where he previously served on its Board of Dean's Advisors. Mr. Scully's global management experience, financial acumen, M&A expertise and investor insights, along with his public company board experience, make him a valuable member of Zoetis Inc. Board.
Robert W. Scully,2010年7月15日起,担任本公司管理合伙人的董事。2007年直到2009年退休,他是Morgan Stanley董事长的办公室成员;之前,他曾担任该公司的全球资本市场部联席总裁与主席、投资银行部副主席。加入Morgan Stanley之前,他曾担任Lehman Brothers 和 Salomon Brothers的总经理。2013年6月起,他是Zoetis的董事。之前,他曾担任Bank of America Corporation的董事,直到2013年5月,也曾担任GMAC Financial Services 和 MSCI Inc.的董事。他获得了Princeton University的学士学位、Harvard Business School的工商管理硕士学位。他在金融服务行业有着35年的丰富经验,为本公司的监管带来了重要的专业知识。另外,他在全球性金融服务 公司的领导任职经验,也为本公司在美国和国际上的许多事务带来了行业性的视角,比如业务开发、人才开发、高级客户关系管理、战略行动、风险管理、审核与财务报告。
Robert W. Scully,is a former member of the Office of the Chairman of Morgan Stanley, a role in which he served from 2007 until January 2009. Prior to his service as a member of the Office of the Chairman of Morgan Stanley, he served as Co-President responsible for Asset Management, Discover Credit Cards from 2006 to 2007, where several global business units reported directly to him, and he was responsible for marketing and sales. Prior to assuming the position of Co-President at Morgan Stanley, he served as Chairman of Global Capital Markets from 2004 to 2006, Vice Chairman of Investment Banking from 1999 to 2006, and Managing Director from 1996 to 2009, where he gained human capital management experience. Prior to joining Morgan Stanley in 1996, Mr. Scully served as Managing Director at Lehman Brothers from 1993 to 1996, as Managing Director at Scully Brothers Foss & Wight from 1989 to 1993 and as Managing Director at Salomon Brothers in Investment Banking and Capital Markets from 1984 to 1989. Mr. Scully has over 30 years of leadership experience in the global financial services industry, particularly in providing strategic advice to global enterprises regarding M&A transactions.In addition to his service on the Zoetis Board of Directors, Mr. Scully currently serves as a member of the Board of Directors of KKR & Co. Inc. (since July 2010) and Chubb Limited (since May 2014). Previously, he served as a member of the Boards of Directors of UBS Group AG, Bank of America Corporation, GMAC Financial Services and MSCI Inc., and as a Public Governor of FINRA, Inc., the Financial Industry Regulatory Authority. Mr. Scully holds a bachelor's degree from Princeton University and an MBA from Harvard Business School, where he previously served on its Board of Dean's Advisors. Mr. Scully's global management experience, financial acumen, M&A expertise and investor insights, along with his public company board experience, make him a valuable member of Zoetis Inc. Board.
Frank A. D'Amelio

Frank A. D'Amelio,自2010年12月起,他担任业务运营执行副总裁及财务总监。2007年9月至2010年12月,是高级副总裁兼财务总监。在加入辉瑞公司前,自2006年11月至2007年8月,他是阿尔卡特朗讯的整合高级执行副总裁及首席行政官。他是Zoetis公司和Humana公司的董事,是Humana公司审计委员会的主席。他是新泽西州独立学院基金会和吉伦布鲁尔学校的董事。


Frank A. D'Amelio,is the former Executive Vice President and Chief Financial Officer of Pfizer Inc., a global pharmaceutical company (June 2020 to May 2022), and a member of Pfizer's Senior Executive Leadership Team. Mr. D'Amelio currently serves as a CFO in residence at the Deloitte CFO Academy. From June 2020 through December 2021, Mr. D'Amelio also served as Pfizer's Executive Vice President, Global Supply and Business Operations. Mr. D'Amelio previously served as Pfizer's Executive Vice President, Business Operations and Global Supply and Chief Financial Officer from October 2018 until June 2020 and Executive Vice President, Business Operations and Chief Financial Officer from December 2010 to September 2018. He joined Pfizer in September 2007 and held various positions, including Senior Vice President and Chief Financial Officer. During Mr. D'Amelio's tenure at Pfizer, he led many acquisitions and partnerships valued at nearly $200 billion, including numerous transformative transactions, such as the acquisition of Wyeth as well as the divestitures of the animal health, consumer health and mature products businesses, and oversaw the company's information technology function and global supply chain. From November 2006 to August 2007, Mr. D'Amelio was the Senior Executive Vice President of Integration and Chief Administrative Officer at Alcatel-Lucent, S.A., a global telecommunications equipment company. From January 2006 to November 2006, Mr. D'Amelio was the Chief Operating Officer of Lucent Technologies, with responsibility for leading business operations, including sales, the product groups, the services business, the supply chain, information technology operations, human resources and labor relations. From May 2001 until January 2006, he was appointed Executive Vice President, Administration, and Chief Financial Officer of Lucent.In addition to his service on the Zoetis Board of Directors, Mr. D'Amelio currently serves as a member of the Board of Directors of Humana Inc. (since September 2003), Hewlett Packard Enterprise (since January 2023), and Catalent Inc. (since August 2023). He also formerly served as a member of the National Advisory Board of JPMorgan Chase & Co. Mr. D'Amelio earned his bachelor's degree in Accounting from St. Peter's College and his MBA in Finance from St. John's University. Mr. D'Amelio's global senior management experience, finance and operational expertise, and knowledge of the pharmaceuticals industry, along with his public company board experience, make him a valuable member of Zoetis Inc. Board.
Frank A. D'Amelio,自2010年12月起,他担任业务运营执行副总裁及财务总监。2007年9月至2010年12月,是高级副总裁兼财务总监。在加入辉瑞公司前,自2006年11月至2007年8月,他是阿尔卡特朗讯的整合高级执行副总裁及首席行政官。他是Zoetis公司和Humana公司的董事,是Humana公司审计委员会的主席。他是新泽西州独立学院基金会和吉伦布鲁尔学校的董事。
Frank A. D'Amelio,is the former Executive Vice President and Chief Financial Officer of Pfizer Inc., a global pharmaceutical company (June 2020 to May 2022), and a member of Pfizer's Senior Executive Leadership Team. Mr. D'Amelio currently serves as a CFO in residence at the Deloitte CFO Academy. From June 2020 through December 2021, Mr. D'Amelio also served as Pfizer's Executive Vice President, Global Supply and Business Operations. Mr. D'Amelio previously served as Pfizer's Executive Vice President, Business Operations and Global Supply and Chief Financial Officer from October 2018 until June 2020 and Executive Vice President, Business Operations and Chief Financial Officer from December 2010 to September 2018. He joined Pfizer in September 2007 and held various positions, including Senior Vice President and Chief Financial Officer. During Mr. D'Amelio's tenure at Pfizer, he led many acquisitions and partnerships valued at nearly $200 billion, including numerous transformative transactions, such as the acquisition of Wyeth as well as the divestitures of the animal health, consumer health and mature products businesses, and oversaw the company's information technology function and global supply chain. From November 2006 to August 2007, Mr. D'Amelio was the Senior Executive Vice President of Integration and Chief Administrative Officer at Alcatel-Lucent, S.A., a global telecommunications equipment company. From January 2006 to November 2006, Mr. D'Amelio was the Chief Operating Officer of Lucent Technologies, with responsibility for leading business operations, including sales, the product groups, the services business, the supply chain, information technology operations, human resources and labor relations. From May 2001 until January 2006, he was appointed Executive Vice President, Administration, and Chief Financial Officer of Lucent.In addition to his service on the Zoetis Board of Directors, Mr. D'Amelio currently serves as a member of the Board of Directors of Humana Inc. (since September 2003), Hewlett Packard Enterprise (since January 2023), and Catalent Inc. (since August 2023). He also formerly served as a member of the National Advisory Board of JPMorgan Chase & Co. Mr. D'Amelio earned his bachelor's degree in Accounting from St. Peter's College and his MBA in Finance from St. John's University. Mr. D'Amelio's global senior management experience, finance and operational expertise, and knowledge of the pharmaceuticals industry, along with his public company board experience, make him a valuable member of Zoetis Inc. Board.
Michael B. McCallister

Michael B. McCallister, 2010至2013年,他担任Humana Inc.的董事会主席, 该公司是提供一系列保险产品和健康与福利服务的医疗保健公司,领导董事会的公司管理事务。1974年,他加入Humana;2000年2月至2012年12月31日退休,担任其首席执行官。担任首席执行官期间,Humana获得了业内一流以人为本的创新公司称号,借力产品、流程和技术帮助个人掌控自己的健康。他曾在Business Roundtable担任多年的董事会成员,是其健康与退休任务小组前主席。他目前是AT&T的董事会成员、审计委员会成员以及Fifth Third Bank和Bellarmine University的董事会成员。他在路易斯安那州立大学(Louisiana Tech University)获得会计学学士学位,在佩珀代因大学(Pepperdine University)获得工商管理硕士学位。


Michael B. McCallister,is the former Chairman of the Board and CEO of Humana Inc. Mr. McCallister joined Humana, a health care company offering insurance products and health and welfare services, including insurance products sold directly to consumers, in 1974 and served as its Chief Executive Officer from February 2000 until his retirement in December 2012. During his tenure as CEO Mr. McCallister led numerous M&A transactions, had significant oversight responsibility for the company's compliance, human capital management and marketing and sales functions and gained research and development experience through oversight of the company's development of insurance products for governments, individuals and companies. Mr. McCallister also served as Chairman of the Board of Humana from August 2010 to December 2013.In addition to his service on the Zoetis Board of Directors, Mr. McCallister currently serves as a member of the Boards of Directors of AT&T (since February 2013) and Fifth Third Bank (since November 2011). Mr. McCallister formerly served on the Board of Directors of National City Corp. Mr. McCallister also served for many years on the Board of the Business Roundtable and was Chairman of its Health and Retirement Task Force. Mr. McCallister holds a bachelor's degree in Accounting from Louisiana Tech University and an MBA from Pepperdine University. Mr. McCallister's senior management experience in the healthcare industry and operational expertise, along with his public company board experience, make him a valuable member of Zoetis Inc. Board.
Michael B. McCallister, 2010至2013年,他担任Humana Inc.的董事会主席, 该公司是提供一系列保险产品和健康与福利服务的医疗保健公司,领导董事会的公司管理事务。1974年,他加入Humana;2000年2月至2012年12月31日退休,担任其首席执行官。担任首席执行官期间,Humana获得了业内一流以人为本的创新公司称号,借力产品、流程和技术帮助个人掌控自己的健康。他曾在Business Roundtable担任多年的董事会成员,是其健康与退休任务小组前主席。他目前是AT&T的董事会成员、审计委员会成员以及Fifth Third Bank和Bellarmine University的董事会成员。他在路易斯安那州立大学(Louisiana Tech University)获得会计学学士学位,在佩珀代因大学(Pepperdine University)获得工商管理硕士学位。
Michael B. McCallister,is the former Chairman of the Board and CEO of Humana Inc. Mr. McCallister joined Humana, a health care company offering insurance products and health and welfare services, including insurance products sold directly to consumers, in 1974 and served as its Chief Executive Officer from February 2000 until his retirement in December 2012. During his tenure as CEO Mr. McCallister led numerous M&A transactions, had significant oversight responsibility for the company's compliance, human capital management and marketing and sales functions and gained research and development experience through oversight of the company's development of insurance products for governments, individuals and companies. Mr. McCallister also served as Chairman of the Board of Humana from August 2010 to December 2013.In addition to his service on the Zoetis Board of Directors, Mr. McCallister currently serves as a member of the Boards of Directors of AT&T (since February 2013) and Fifth Third Bank (since November 2011). Mr. McCallister formerly served on the Board of Directors of National City Corp. Mr. McCallister also served for many years on the Board of the Business Roundtable and was Chairman of its Health and Retirement Task Force. Mr. McCallister holds a bachelor's degree in Accounting from Louisiana Tech University and an MBA from Pepperdine University. Mr. McCallister's senior management experience in the healthcare industry and operational expertise, along with his public company board experience, make him a valuable member of Zoetis Inc. Board.
Gregory Norden

Gregory Norden自2012年7月成为董事会成员,同时担任审计委员会主席。从1989年到2010年,Norden先生在Wyeth/American Home Products担任各种高级职务,他在该公司担任最后的职务是高级副总裁和首席财务官。此前,Norden先生担任Wyeth Pharmaceuticals的执行副总裁和首席财务官。在Wyeth任职前,Norden先生在Arthur Andersen & Company担任审计经理。Norden先生还任职于WelchAllyn和Zoetis Inc.的董事会,前者是主要的全球医疗诊断设备提供商;后者是全球动物健康药物和疫苗的发现、开发、生产和商业化的领导者。他还是Human Genome Sciences的前董事,该公司在2012年8月被GlaxoSmithKline收购。Norden先生从长岛大学(Long Island University)C.W. Post分校获得会计学硕士学位,从纽约州立大学普拉茨堡(State University of New York - Plattsburgh)获得管理学/经济学学士学位。


Gregory Norden,is the former Chief Financial Officer of Wyeth, a global pharmaceutical and health care products company, where he had various responsibilities, including driving the company's M&A strategy. Prior to his role as Chief Financial Officer of Wyeth, Mr. Norden held various senior positions with Wyeth Pharmaceuticals, formerly American Home Products (from 1989 to October 2009), including experience working with Fort Dodge Animal Health, a manufacturer of animal health products, that was part of Wyeth. Mr. Norden is currently the Managing Director of G9 Capital Group LLC (since January 2010), which invests in early-stage ventures and provides corporate finance advisory services. Prior to his affiliation with Wyeth, Mr. Norden served as Audit Manager at Arthur Andersen & Co, working primarily with multinational companies in the life sciences, consumer goods and financial services industries. Mr. Norden has over 20 years of leadership and financial management experience in global healthcare and pharmaceuticals.In addition to his service on the Zoetis Board of Directors, Mr. Norden currently serves as a member of the Board of Directors of NanoString Technologies (since July 2012), Praxis (since March 2019), and Royalty Pharma (since June 2020). Mr. Norden formerly served on the Boards of Directors of Human Genome Sciences, Welch Allyn, Univision and Entasis. Mr. Norden's experience as a senior executive in the global healthcare and pharmaceutical industries, and his finance and consumer products expertise, along with his public company board experience, make him a valuable member of Zoetis Inc. Board.
Gregory Norden自2012年7月成为董事会成员,同时担任审计委员会主席。从1989年到2010年,Norden先生在Wyeth/American Home Products担任各种高级职务,他在该公司担任最后的职务是高级副总裁和首席财务官。此前,Norden先生担任Wyeth Pharmaceuticals的执行副总裁和首席财务官。在Wyeth任职前,Norden先生在Arthur Andersen & Company担任审计经理。Norden先生还任职于WelchAllyn和Zoetis Inc.的董事会,前者是主要的全球医疗诊断设备提供商;后者是全球动物健康药物和疫苗的发现、开发、生产和商业化的领导者。他还是Human Genome Sciences的前董事,该公司在2012年8月被GlaxoSmithKline收购。Norden先生从长岛大学(Long Island University)C.W. Post分校获得会计学硕士学位,从纽约州立大学普拉茨堡(State University of New York - Plattsburgh)获得管理学/经济学学士学位。
Gregory Norden,is the former Chief Financial Officer of Wyeth, a global pharmaceutical and health care products company, where he had various responsibilities, including driving the company's M&A strategy. Prior to his role as Chief Financial Officer of Wyeth, Mr. Norden held various senior positions with Wyeth Pharmaceuticals, formerly American Home Products (from 1989 to October 2009), including experience working with Fort Dodge Animal Health, a manufacturer of animal health products, that was part of Wyeth. Mr. Norden is currently the Managing Director of G9 Capital Group LLC (since January 2010), which invests in early-stage ventures and provides corporate finance advisory services. Prior to his affiliation with Wyeth, Mr. Norden served as Audit Manager at Arthur Andersen & Co, working primarily with multinational companies in the life sciences, consumer goods and financial services industries. Mr. Norden has over 20 years of leadership and financial management experience in global healthcare and pharmaceuticals.In addition to his service on the Zoetis Board of Directors, Mr. Norden currently serves as a member of the Board of Directors of NanoString Technologies (since July 2012), Praxis (since March 2019), and Royalty Pharma (since June 2020). Mr. Norden formerly served on the Boards of Directors of Human Genome Sciences, Welch Allyn, Univision and Entasis. Mr. Norden's experience as a senior executive in the global healthcare and pharmaceutical industries, and his finance and consumer products expertise, along with his public company board experience, make him a valuable member of Zoetis Inc. Board.
Paul M. Bisaro

Paul M. Bisaro,自2013年10月他是阿特维斯有限公司的总裁兼首席执行官。自2007年他一直担任总裁兼首席执行官,和阿特维斯原华生制药的董事会成员。于2013年10月,他被任命为董事会董事长。在加入阿特维斯前,他担任Barr制药公司的总裁,首席运营官和董事会成员从1999年至2007年。1992年至1999年,他担任巴尔的总法律顾问。在加入巴尔前,从1989年到1992年,他在温斯顿国际律师事务所和前任公司,主教,库克,赛尔和雷诺工作。他持有密歇根大学常识本科学位和美国华盛顿特区的天主教大学的法学博士学位。


Paul M. Bisaro,is the former Executive Chairman of Amneal Pharmaceuticals, Inc., a global specialty pharmaceutical company, from May 2018 to August 2019. Amneal was formed by the merger of Amneal Pharmaceuticals LLC and Impax Laboratories, Inc., which Mr. Bisaro led during his tenure as President and Chief Executive Officer from March 2017 to May 2018, during which he oversaw, among others, all marketing and sales activities. Mr. Bisaro was previously the Executive Chairman of the Board of Directors of Allergan plc (formerly Actavis plc) from July 2014 to October 2016, where he played a leading role in growing the company through M&A activity. Until June 2014, Mr. Bisaro served as Board Chairman, President and Chief Executive Officer of Actavis (formerly Watson Pharmaceuticals), a global pharmaceutical company. He was appointed President, Chief Executive Officer and a member of the Board of Directors of Watson in September 2007 and was later appointed Board Chairman in October 2013. Prior to Watson, Mr. Bisaro was President, Chief Operating Officer and member of the Board of Directors of Barr Pharmaceuticals, Inc., a global specialty and generic drug manufacturer where he was responsible for global manufacturing operations. Mr. Bisaro served as Barr's General Counsel from 1992 to 1999, and from 1997 to 1999 he served in various additional capacities including Senior Vice President—Strategic Business Development. Mr. Bisaro brings nearly 30 years of experience in various legal and executive leadership positions in the pharmaceutical industry.In addition to his service on the Zoetis Board, Mr. Bisaro serves as Chair of the Board of Mallinckrodt plc (since February 2024, and previously from June 2022 - November 2023) and on the Board of Directors of Myriad Genetics, Inc. (since October 2022). Mr. Bisaro previously served on the Boards of Directors of Allergan plc (and its predecessor companies), Zimmer Biomet Holdings, Inc., Amneal Pharmaceuticals (and its predecessor Impax) and TherapeuticsMD, Inc. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from The Catholic University of America in Washington, D.C. Mr. Bisaro's global business, management and leadership experience, his understanding of the pharmaceutical industry, and his public company board experience make him a valuable member of Zoetis Inc. Board.
Paul M. Bisaro,自2013年10月他是阿特维斯有限公司的总裁兼首席执行官。自2007年他一直担任总裁兼首席执行官,和阿特维斯原华生制药的董事会成员。于2013年10月,他被任命为董事会董事长。在加入阿特维斯前,他担任Barr制药公司的总裁,首席运营官和董事会成员从1999年至2007年。1992年至1999年,他担任巴尔的总法律顾问。在加入巴尔前,从1989年到1992年,他在温斯顿国际律师事务所和前任公司,主教,库克,赛尔和雷诺工作。他持有密歇根大学常识本科学位和美国华盛顿特区的天主教大学的法学博士学位。
Paul M. Bisaro,is the former Executive Chairman of Amneal Pharmaceuticals, Inc., a global specialty pharmaceutical company, from May 2018 to August 2019. Amneal was formed by the merger of Amneal Pharmaceuticals LLC and Impax Laboratories, Inc., which Mr. Bisaro led during his tenure as President and Chief Executive Officer from March 2017 to May 2018, during which he oversaw, among others, all marketing and sales activities. Mr. Bisaro was previously the Executive Chairman of the Board of Directors of Allergan plc (formerly Actavis plc) from July 2014 to October 2016, where he played a leading role in growing the company through M&A activity. Until June 2014, Mr. Bisaro served as Board Chairman, President and Chief Executive Officer of Actavis (formerly Watson Pharmaceuticals), a global pharmaceutical company. He was appointed President, Chief Executive Officer and a member of the Board of Directors of Watson in September 2007 and was later appointed Board Chairman in October 2013. Prior to Watson, Mr. Bisaro was President, Chief Operating Officer and member of the Board of Directors of Barr Pharmaceuticals, Inc., a global specialty and generic drug manufacturer where he was responsible for global manufacturing operations. Mr. Bisaro served as Barr's General Counsel from 1992 to 1999, and from 1997 to 1999 he served in various additional capacities including Senior Vice President—Strategic Business Development. Mr. Bisaro brings nearly 30 years of experience in various legal and executive leadership positions in the pharmaceutical industry.In addition to his service on the Zoetis Board, Mr. Bisaro serves as Chair of the Board of Mallinckrodt plc (since February 2024, and previously from June 2022 - November 2023) and on the Board of Directors of Myriad Genetics, Inc. (since October 2022). Mr. Bisaro previously served on the Boards of Directors of Allergan plc (and its predecessor companies), Zimmer Biomet Holdings, Inc., Amneal Pharmaceuticals (and its predecessor Impax) and TherapeuticsMD, Inc. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from The Catholic University of America in Washington, D.C. Mr. Bisaro's global business, management and leadership experience, his understanding of the pharmaceutical industry, and his public company board experience make him a valuable member of Zoetis Inc. Board.
Sanjay Khosla

Sanjay Khosla,2007年至2013年。作为总裁,卡夫食品,发展市场现在MondelēzInternational从2007年到2013年Khosla先生将50亿美元的业务转变为160亿美元的业务,同时显着提高了盈利能力。他还在2004年至2007年的三年任期内担任动物健康经验,担任Fonterra Brands and Food Service的总经理,该公司是家位于新西兰的跨国乳品合作社。 Khosla先生是NIIT,Ltd.(一家涉及技术相关教育服务的公司)以及Iconix Brand Group,Inc.的董事会成员,该公司授权和营销一系列消费品牌。从2008年10月至2015年6月,他在Best Buy,Inc.的董事会任职,该公司是消费电子,个人电脑,娱乐软件和家用电器的专业零售商。 Khosla先生拥有新德里印度理工学院的电子工程学士学位。 Khosla先生还完成了哈佛商学院的高级管理课程。 Khosla先生目前是西北大学凯洛格管理学院的高级研究员和兼职教授。


Sanjay Khosla,is the former Executive Vice President and President, Developing Markets of Mondelēz International, Inc., a global food, beverage and snack company (January 2007 to March 2013) and is currently a senior fellow and adjunct professor at the Kellogg School of Management, Northwestern University (since June 2013) and a Senior Advisor for the Boston Consulting Group (since April 2013). Mr. Khosla is also the CEO of Bunnik LLC, a management consulting firm (since 2013). As President, Developing Markets of Kraft Foods (now Mondelēz International), Mr. Khosla transformed the $5 billion business into a $16 billion business, and gained leadership experience in manufacturing and supply, marketing and sales and M&A. Mr. Khosla brings more than 35 years of international business experience from his career with food, beverage and consumer product leaders such as Mondelēz, Kraft, Fonterra and Unilever, where he managed various business units, particularly in developing markets, oversaw human capital management functions and was responsible for R&D and innovation in a number of roles. He also has animal health experience from his two-year tenure, from 2004 to 2006, as Managing Director of Fonterra Brands and Food Service, a multinational dairy cooperative based in New Zealand.In addition to his service on the Zoetis Board of Directors, Mr. Khosla currently serves as a member of the Board of Directors of Igniting Consumer Growth Acquisition Company Limited (since September 2021) and also serves on a number of private company Boards of Directors, including the Board of Directors of Qualsights (since November 2022). Mr. Khosla formerly served on the Boards of Directors of Best Buy, Inc., NIIT, Ltd. and Iconix Brand Group, Inc. Mr. Khosla holds a bachelor's degree in Electrical Engineering from the Indian Institute of Technology in New Delhi. Mr. Khosla also completed the Advance Management Program at Harvard Business School. Mr. Khosla's international business and management experience and consumer products marketing and sales expertise, along with his public company board experience, make him a valuable member of Zoetis Inc. Board.
Sanjay Khosla,2007年至2013年。作为总裁,卡夫食品,发展市场现在MondelēzInternational从2007年到2013年Khosla先生将50亿美元的业务转变为160亿美元的业务,同时显着提高了盈利能力。他还在2004年至2007年的三年任期内担任动物健康经验,担任Fonterra Brands and Food Service的总经理,该公司是家位于新西兰的跨国乳品合作社。 Khosla先生是NIIT,Ltd.(一家涉及技术相关教育服务的公司)以及Iconix Brand Group,Inc.的董事会成员,该公司授权和营销一系列消费品牌。从2008年10月至2015年6月,他在Best Buy,Inc.的董事会任职,该公司是消费电子,个人电脑,娱乐软件和家用电器的专业零售商。 Khosla先生拥有新德里印度理工学院的电子工程学士学位。 Khosla先生还完成了哈佛商学院的高级管理课程。 Khosla先生目前是西北大学凯洛格管理学院的高级研究员和兼职教授。
Sanjay Khosla,is the former Executive Vice President and President, Developing Markets of Mondelēz International, Inc., a global food, beverage and snack company (January 2007 to March 2013) and is currently a senior fellow and adjunct professor at the Kellogg School of Management, Northwestern University (since June 2013) and a Senior Advisor for the Boston Consulting Group (since April 2013). Mr. Khosla is also the CEO of Bunnik LLC, a management consulting firm (since 2013). As President, Developing Markets of Kraft Foods (now Mondelēz International), Mr. Khosla transformed the $5 billion business into a $16 billion business, and gained leadership experience in manufacturing and supply, marketing and sales and M&A. Mr. Khosla brings more than 35 years of international business experience from his career with food, beverage and consumer product leaders such as Mondelēz, Kraft, Fonterra and Unilever, where he managed various business units, particularly in developing markets, oversaw human capital management functions and was responsible for R&D and innovation in a number of roles. He also has animal health experience from his two-year tenure, from 2004 to 2006, as Managing Director of Fonterra Brands and Food Service, a multinational dairy cooperative based in New Zealand.In addition to his service on the Zoetis Board of Directors, Mr. Khosla currently serves as a member of the Board of Directors of Igniting Consumer Growth Acquisition Company Limited (since September 2021) and also serves on a number of private company Boards of Directors, including the Board of Directors of Qualsights (since November 2022). Mr. Khosla formerly served on the Boards of Directors of Best Buy, Inc., NIIT, Ltd. and Iconix Brand Group, Inc. Mr. Khosla holds a bachelor's degree in Electrical Engineering from the Indian Institute of Technology in New Delhi. Mr. Khosla also completed the Advance Management Program at Harvard Business School. Mr. Khosla's international business and management experience and consumer products marketing and sales expertise, along with his public company board experience, make him a valuable member of Zoetis Inc. Board.
Louise M. Parent

Louise M. Parent 于 2014 年至 2021 年 12 月 31 日期间担任 Cleary Gottlieb Steen & Hamilton LLP 律师事务所的法律顾问。从 1993 年至 2013 年退休,Parent 女士担任American Express Company 的执行副总裁兼总法律顾问。 在此期间,她还担任其主要运营子公司American Express Travel Related Services Company 和美国银行子公司美国运通百夫长银行的董事。 Parent 女士目前在 Zoetis, Inc. 董事会任职,Zoetis, Inc. 是一家专注于动物健康的上市公司,此前曾于 2014 年 7 月至 2018 年在德意志银行监事会任职。


Louise M. Parent,is the former Executive Vice President and General Counsel of American Express Company, a global services company that provides consumer charge and credit card products and travel-related services, from 2004 to 2013. From 2014 through December 2021, Ms. Parent served as Of Counsel at the law firm of Cleary Gottlieb Steen & Hamilton LLP. In addition, while at American Express, Ms. Parent led a number of M&A transactions and oversaw the legal function responsible for executing M&A transactions globally. Ms. Parent also served on the Operating Committee and global management team of American Express from 2003 through 2013, was a member of the Board of American Express Centurion Bank through 2013 and served on the Supervisory Board of Deutsche Bank AG from 2014 to 2018.In addition to her service on the Zoetis Board of Directors, Ms. Parent currently serves as a member of the Board of Directors of Fidelity National Information Services Inc. (since November 2017). Ms. Parent holds a bachelor's degree from Smith College and a law degree from Georgetown University Law Center. Ms. Parent's experience and expertise in corporate governance, compliance, risk management and global management, along with her public company board experience and financial literacy, make her a valuable member of Zoetis Inc. Board.
Louise M. Parent 于 2014 年至 2021 年 12 月 31 日期间担任 Cleary Gottlieb Steen & Hamilton LLP 律师事务所的法律顾问。从 1993 年至 2013 年退休,Parent 女士担任American Express Company 的执行副总裁兼总法律顾问。 在此期间,她还担任其主要运营子公司American Express Travel Related Services Company 和美国银行子公司美国运通百夫长银行的董事。 Parent 女士目前在 Zoetis, Inc. 董事会任职,Zoetis, Inc. 是一家专注于动物健康的上市公司,此前曾于 2014 年 7 月至 2018 年在德意志银行监事会任职。
Louise M. Parent,is the former Executive Vice President and General Counsel of American Express Company, a global services company that provides consumer charge and credit card products and travel-related services, from 2004 to 2013. From 2014 through December 2021, Ms. Parent served as Of Counsel at the law firm of Cleary Gottlieb Steen & Hamilton LLP. In addition, while at American Express, Ms. Parent led a number of M&A transactions and oversaw the legal function responsible for executing M&A transactions globally. Ms. Parent also served on the Operating Committee and global management team of American Express from 2003 through 2013, was a member of the Board of American Express Centurion Bank through 2013 and served on the Supervisory Board of Deutsche Bank AG from 2014 to 2018.In addition to her service on the Zoetis Board of Directors, Ms. Parent currently serves as a member of the Board of Directors of Fidelity National Information Services Inc. (since November 2017). Ms. Parent holds a bachelor's degree from Smith College and a law degree from Georgetown University Law Center. Ms. Parent's experience and expertise in corporate governance, compliance, risk management and global management, along with her public company board experience and financial literacy, make her a valuable member of Zoetis Inc. Board.
Willie M. Reed

Willie M. Reed,2007年起担任Purdue University兽医学院院长。Reed博士在动物保健国际和兽医学领域拥有超过38年的经验,任职于Purdue University和密歇根州立大学,并担任美国兽医病理学家学院外交官和美国家禽兽医学院特许外交官。Reed博士曾担任美国兽医学院协会主席、美国兽医实验室诊断师协会主席、美国禽病理学家协会主席和美国兽医协会研究理事会主席。他曾在美国国立卫生研究院和美国农业部的多个委员会任职。Reed博士拥有塔斯基吉大学的DVM和普渡大学的兽医病理学博士学位。


Willie M. Reed,currently serves as the Dean of the College of Veterinary Medicine at Purdue University, a role he has held since January 2007. Prior to his current role Dr. Reed served as Professor of Veterinary Pathology, Chairperson of the Department of Diagnostic Investigation (1997 - December 2006) and Director of the Diagnostic Center for Population and Animal Health (1990 - December 2006) at Michigan State University. Previously Dr. Reed served as chief of Purdue's Avian Diseases Diagnostic Service (1985 - 1990), assistant professor of veterinary pathology (1982 - 1987) and associate professor of veterinary pathology (1987 - 1990). Dr. Reed has more than 40 years of experience in animal health and veterinary medicine, including marketing of diagnostic services for diagnostic laboratories, gained during his tenure at Purdue University and Michigan State University, and as a Diplomate of the American College of Veterinary Pathologists and Charter Diplomate of the American College of Poultry Veterinarians.Dr. Reed has served as President of the Association of American Veterinary Medical Colleges, President of the American Association of Veterinary Laboratory Diagnosticians, President of the American Association of Avian Pathologists and Chair of the American Veterinary Medical Association Council on Research. He has served on a number of committees for the National Institutes of Health and the United States Department of Agriculture. Dr. Reed has a DVM from Tuskegee University and a Ph.D. in Veterinary Pathology from Purdue University. Dr. Reed's experience and expertise in veterinary medicines, diagnostics and vaccines and his thought leadership in the animal health community make him a valuable member of Zoetis Inc. Board.
Willie M. Reed,2007年起担任Purdue University兽医学院院长。Reed博士在动物保健国际和兽医学领域拥有超过38年的经验,任职于Purdue University和密歇根州立大学,并担任美国兽医病理学家学院外交官和美国家禽兽医学院特许外交官。Reed博士曾担任美国兽医学院协会主席、美国兽医实验室诊断师协会主席、美国禽病理学家协会主席和美国兽医协会研究理事会主席。他曾在美国国立卫生研究院和美国农业部的多个委员会任职。Reed博士拥有塔斯基吉大学的DVM和普渡大学的兽医病理学博士学位。
Willie M. Reed,currently serves as the Dean of the College of Veterinary Medicine at Purdue University, a role he has held since January 2007. Prior to his current role Dr. Reed served as Professor of Veterinary Pathology, Chairperson of the Department of Diagnostic Investigation (1997 - December 2006) and Director of the Diagnostic Center for Population and Animal Health (1990 - December 2006) at Michigan State University. Previously Dr. Reed served as chief of Purdue's Avian Diseases Diagnostic Service (1985 - 1990), assistant professor of veterinary pathology (1982 - 1987) and associate professor of veterinary pathology (1987 - 1990). Dr. Reed has more than 40 years of experience in animal health and veterinary medicine, including marketing of diagnostic services for diagnostic laboratories, gained during his tenure at Purdue University and Michigan State University, and as a Diplomate of the American College of Veterinary Pathologists and Charter Diplomate of the American College of Poultry Veterinarians.Dr. Reed has served as President of the Association of American Veterinary Medical Colleges, President of the American Association of Veterinary Laboratory Diagnosticians, President of the American Association of Avian Pathologists and Chair of the American Veterinary Medical Association Council on Research. He has served on a number of committees for the National Institutes of Health and the United States Department of Agriculture. Dr. Reed has a DVM from Tuskegee University and a Ph.D. in Veterinary Pathology from Purdue University. Dr. Reed's experience and expertise in veterinary medicines, diagnostics and vaccines and his thought leadership in the animal health community make him a valuable member of Zoetis Inc. Board.
Vanessa Broadhurst

Vanessa Broadhurst目前在强生担任全球企业事务执行副总裁,强生公司是一家专注于与人类健康和福祉相关的产品的全球性公司,她还是强生公司执行委员会的成员。在强生,Broadhurst女士领导公司的企业营销、全球传播、健康与保健解决方案、全球公共卫生和慈善职能。任职期间,布罗德赫斯特女士的职责包括领导大量员工的人力资本管理。在2023年Kenvue从强生分离出消费者之前,她还领导过消费者沟通、设计,包括包装,以及产品设计。在目前任职于强生之前,Broadhurst女士曾于2019年至2021年12月担任公司集团主席、全球医药商业战略,并于2017年至2018年担任心血管和代谢领域总裁。在加入强生之前,Broadhurst女士在安进担任心血管和骨骼业务部门总经理(2014-2017年),任职期间,她在并购活动、管道开发和新产品发布战略方面担任领导职务。此前她曾在安进担任炎症和心血管事业部总经理(2013-2014年)。从2005年到2013年,布罗德赫斯特女士在强生担任过多个高级领导职务。在2005年之前,Broadhurst女士曾担任诺华公司全球胃肠病学市场营销主管(2003-2005年),并在雅培担任过各种职务,承担着越来越大的责任(1994-2003年)。Broadhurst女士担任执行领导委员会(ELC)成员和AD委员会董事会成员。她获得了密歇根大学罗斯商学院的工商管理硕士学位,她是学院的财团研究员,并获得了科罗拉多大学博尔德分校的文学学士学位。Broadhurst女士在消费者医疗保健营销和数字传播方面的专长,以及她在全球制药行业的业务经验,使她成为硕腾公司董事会的宝贵成员。


Vanessa Broadhurst,currently serves as the Executive Vice President, Global Corporate Affairs, at Johnson & Johnson, a global company focused on products related to human health and well-being, where she is also a member of the company's Executive Committee. At Johnson & Johnson, Ms. Broadhurst leads the company's corporate marketing, global communications, Health & Wellness Solutions, global public health and philanthropy functions. In this role, Ms. Broadhurst's responsibilities include leading human capital management for a significant number of employees. Previous to the consumer separation of Kenvue from Johnson & Johnson in 2023, she additionally led consumer communications, design, including packaging, and product design.Prior to her current role at Johnson & Johnson, Ms. Broadhurst served as Company Group Chairman, Global Commercial Strategy for Pharmaceuticals from 2019 to December 2021 and President, Cardiovascular and Metabolism from 2017 to 2018. Prior to Johnson & Johnson, Ms. Broadhurst was General Manager, Cardiovascular and Bone Business Units at Amgen (2014 - 2017), in these roles she had a leadership position in M&A activity, pipeline development and new product launch strategy. Previously she served as General Manager, Inflammation and Cardiovascular Business Units at Amgen (2013 - 2014). From 2005 to 2013 Ms. Broadhurst served in various senior leadership roles at Johnson & Johnson. Prior to 2005 Ms. Broadhurst was Head, Global Gastroenterology Marketing at Novartis (2003 - 2005) and served in various roles of increasing responsibility at Abbott Laboratories (1994 - 2003).Ms. Broadhurst serves as a member of The Executive Leadership Council (ELC) and as a Board member of the Ad Council. She received a Master of Business Administration from the Ross School of Business at the University of Michigan, where she was a Consortium Fellow, and a Bachelor of Arts degree from the University of Colorado, Boulder. Ms. Broadhurst's consumer healthcare marketing and digital communications expertise, as well as her business experience with the global pharmaceutical industry, make her a valuable member of Zoetis Inc. Board.
Vanessa Broadhurst目前在强生担任全球企业事务执行副总裁,强生公司是一家专注于与人类健康和福祉相关的产品的全球性公司,她还是强生公司执行委员会的成员。在强生,Broadhurst女士领导公司的企业营销、全球传播、健康与保健解决方案、全球公共卫生和慈善职能。任职期间,布罗德赫斯特女士的职责包括领导大量员工的人力资本管理。在2023年Kenvue从强生分离出消费者之前,她还领导过消费者沟通、设计,包括包装,以及产品设计。在目前任职于强生之前,Broadhurst女士曾于2019年至2021年12月担任公司集团主席、全球医药商业战略,并于2017年至2018年担任心血管和代谢领域总裁。在加入强生之前,Broadhurst女士在安进担任心血管和骨骼业务部门总经理(2014-2017年),任职期间,她在并购活动、管道开发和新产品发布战略方面担任领导职务。此前她曾在安进担任炎症和心血管事业部总经理(2013-2014年)。从2005年到2013年,布罗德赫斯特女士在强生担任过多个高级领导职务。在2005年之前,Broadhurst女士曾担任诺华公司全球胃肠病学市场营销主管(2003-2005年),并在雅培担任过各种职务,承担着越来越大的责任(1994-2003年)。Broadhurst女士担任执行领导委员会(ELC)成员和AD委员会董事会成员。她获得了密歇根大学罗斯商学院的工商管理硕士学位,她是学院的财团研究员,并获得了科罗拉多大学博尔德分校的文学学士学位。Broadhurst女士在消费者医疗保健营销和数字传播方面的专长,以及她在全球制药行业的业务经验,使她成为硕腾公司董事会的宝贵成员。
Vanessa Broadhurst,currently serves as the Executive Vice President, Global Corporate Affairs, at Johnson & Johnson, a global company focused on products related to human health and well-being, where she is also a member of the company's Executive Committee. At Johnson & Johnson, Ms. Broadhurst leads the company's corporate marketing, global communications, Health & Wellness Solutions, global public health and philanthropy functions. In this role, Ms. Broadhurst's responsibilities include leading human capital management for a significant number of employees. Previous to the consumer separation of Kenvue from Johnson & Johnson in 2023, she additionally led consumer communications, design, including packaging, and product design.Prior to her current role at Johnson & Johnson, Ms. Broadhurst served as Company Group Chairman, Global Commercial Strategy for Pharmaceuticals from 2019 to December 2021 and President, Cardiovascular and Metabolism from 2017 to 2018. Prior to Johnson & Johnson, Ms. Broadhurst was General Manager, Cardiovascular and Bone Business Units at Amgen (2014 - 2017), in these roles she had a leadership position in M&A activity, pipeline development and new product launch strategy. Previously she served as General Manager, Inflammation and Cardiovascular Business Units at Amgen (2013 - 2014). From 2005 to 2013 Ms. Broadhurst served in various senior leadership roles at Johnson & Johnson. Prior to 2005 Ms. Broadhurst was Head, Global Gastroenterology Marketing at Novartis (2003 - 2005) and served in various roles of increasing responsibility at Abbott Laboratories (1994 - 2003).Ms. Broadhurst serves as a member of The Executive Leadership Council (ELC) and as a Board member of the Ad Council. She received a Master of Business Administration from the Ross School of Business at the University of Michigan, where she was a Consortium Fellow, and a Bachelor of Arts degree from the University of Colorado, Boulder. Ms. Broadhurst's consumer healthcare marketing and digital communications expertise, as well as her business experience with the global pharmaceutical industry, make her a valuable member of Zoetis Inc. Board.

高管简历

中英对照 |  中文 |  英文
Kristin C. Peck

Kristin C. Peck,自2020年1月起担任Zoetis公司首席执行官自2019年10月起担任董事。在担任首席执行官之前,Peck女士于2018年3月至2019年12月在Zoetis担任执行副总裁兼集团总裁,负责美国业务、业务发展和战略。Peck女士曾于2015年5月至2018年2月担任Zoetis公司执行副总裁兼美国业务总裁,并于2012年10月至2015年4月担任执行副总裁兼集团总裁。在担任这些职务期间,Peck女士帮助Zoetis Inc.完成了Zoetis在2013年的首次公开发行,并推动了全球制造和供应、全球家禽、全球诊断、企业发展、新产品营销和全球市场研究等领域的变革。Peck女士于2004年加入Pfizer,担任过多个职位,包括全球业务发展和创新执行副总裁,以及Pfizer执行领导团队的成员。


Kristin C. Peck,currently serves as Zoetis' Chief Executive Officer, a role she has held since January 2020, and as member of the Board of Directors since October 2019. Prior to becoming CEO at Zoetis, the global leader in the animal health industry, Ms. Peck was Executive Vice President and Group President, U.S. Operations, Business Development and Strategy at Zoetis from March 2018 to December 2019. Ms. Peck previously served as Zoetis Inc. Executive Vice President and President, U.S. Operations from May 2015 to February 2018 and Executive Vice President and Group President from October 2012 through April 2015, where she had oversight for Zoetis Inc. business development, global manufacturing and supply and marketing and sales functions. In these roles, Ms. Peck helped Zoetis Inc. her Zoetis through its Initial Public Offering in 2013 and has been a driving force of change in areas including Global Manufacturing and Supply, Global Poultry, Global Diagnostics, Corporate Development, and New Product Marketing and Global Market Research. Before joining Zoetis, Ms. Peck served as Executive Vice President, Worldwide Business Development and Innovation at Pfizer Inc. (February 2004 - October 2012) and as a member of Pfizer's Executive Leadership Team, where she gained human capital management experience. Prior to joining Pfizer, Ms. Peck held roles at The Boston Consulting Group (BCG) (1999 - 2004) as well as in private equity and real estate finance at The Prudential Realty Group, The O'Connor Group and J.P. Morgan.In addition to her service on the Zoetis Board of Directors, Ms. Peck currently serves as a member of the Board of Directors of BlackRock (since September 2021), the Board of Trustees of Mayo Clinic and of the Board of Directors of Catalyst, a global non-profit that helps companies accelerate women into leadership, and she formerly served on the Board of Directors of Thomson Reuters. Ms. Peck is a member of the Business Roundtable, The Business Council and is also a member of the Columbia Business School Board of Directors. Ms. Peck holds a bachelor's degree from Georgetown University and an MBA from Columbia Business School. Ms. Peck's knowledge and leadership of the Company as Zoetis Inc. current CEO, her animal health and pharmaceutical industry experience, and her global operational expertise, along with her public company board experience, make her a valuable member of Zoetis Inc. Board.
Kristin C. Peck,自2020年1月起担任Zoetis公司首席执行官自2019年10月起担任董事。在担任首席执行官之前,Peck女士于2018年3月至2019年12月在Zoetis担任执行副总裁兼集团总裁,负责美国业务、业务发展和战略。Peck女士曾于2015年5月至2018年2月担任Zoetis公司执行副总裁兼美国业务总裁,并于2012年10月至2015年4月担任执行副总裁兼集团总裁。在担任这些职务期间,Peck女士帮助Zoetis Inc.完成了Zoetis在2013年的首次公开发行,并推动了全球制造和供应、全球家禽、全球诊断、企业发展、新产品营销和全球市场研究等领域的变革。Peck女士于2004年加入Pfizer,担任过多个职位,包括全球业务发展和创新执行副总裁,以及Pfizer执行领导团队的成员。
Kristin C. Peck,currently serves as Zoetis' Chief Executive Officer, a role she has held since January 2020, and as member of the Board of Directors since October 2019. Prior to becoming CEO at Zoetis, the global leader in the animal health industry, Ms. Peck was Executive Vice President and Group President, U.S. Operations, Business Development and Strategy at Zoetis from March 2018 to December 2019. Ms. Peck previously served as Zoetis Inc. Executive Vice President and President, U.S. Operations from May 2015 to February 2018 and Executive Vice President and Group President from October 2012 through April 2015, where she had oversight for Zoetis Inc. business development, global manufacturing and supply and marketing and sales functions. In these roles, Ms. Peck helped Zoetis Inc. her Zoetis through its Initial Public Offering in 2013 and has been a driving force of change in areas including Global Manufacturing and Supply, Global Poultry, Global Diagnostics, Corporate Development, and New Product Marketing and Global Market Research. Before joining Zoetis, Ms. Peck served as Executive Vice President, Worldwide Business Development and Innovation at Pfizer Inc. (February 2004 - October 2012) and as a member of Pfizer's Executive Leadership Team, where she gained human capital management experience. Prior to joining Pfizer, Ms. Peck held roles at The Boston Consulting Group (BCG) (1999 - 2004) as well as in private equity and real estate finance at The Prudential Realty Group, The O'Connor Group and J.P. Morgan.In addition to her service on the Zoetis Board of Directors, Ms. Peck currently serves as a member of the Board of Directors of BlackRock (since September 2021), the Board of Trustees of Mayo Clinic and of the Board of Directors of Catalyst, a global non-profit that helps companies accelerate women into leadership, and she formerly served on the Board of Directors of Thomson Reuters. Ms. Peck is a member of the Business Roundtable, The Business Council and is also a member of the Columbia Business School Board of Directors. Ms. Peck holds a bachelor's degree from Georgetown University and an MBA from Columbia Business School. Ms. Peck's knowledge and leadership of the Company as Zoetis Inc. current CEO, her animal health and pharmaceutical industry experience, and her global operational expertise, along with her public company board experience, make her a valuable member of Zoetis Inc. Board.
Wetteny Joseph

Wetteny Joseph,自2021年6月起担任Zoetis Inc. 执行副总裁兼首席财务官。Joseph先生从Catalent加入Zoetis Inc. ,在那里他服务了13年,最近一次是在2018年2月至2021年5月担任Catalent的高级副总裁兼首席财务官。Joseph先生于2008年加入Catalent,担任副总裁兼公司财务总监,并担任高级财务职位,直至2015年10月被任命为公司主要业务部门之一的临床供应服务总裁。在加入Catalent之前,Joseph先生在工业分销公司HD Supply担任过各种高级财务职位,包括其管道和暖通空调业务部门的首席财务官。他还曾担任Hughes Supply的公司财务总监,Hughes Supply是财富500强纽约证券交易所上市公司,被Home Depot收购并成为HD Supply的一部分。在他的早期职业生涯中,Joseph先生在普华永道工作了六年,担任多个行业的审计师和战略财务顾问。


Wetteny Joseph,has served as Zoetis Inc. Executive Vice President and Chief Financial Officer since June 2021. Mr. Joseph joined Zoetis from Catalent, where he served for 13 years, most recently as Senior Vice President and Chief Financial Officer of Catalent from February 2018 to May 2021. Mr. Joseph joined Catalent in September 2008 where he served as Corporate Controller until October 2012, then as Vice President Finance across multiple business units until October 2015, when he was named President, Clinical Supply Services, one of the company's principal business units. Before joining Catalent, Mr. Joseph held a variety of senior financial positions at the industrial distribution company HD Supply, including as CFO of its plumbing and HVAC business unit. He also served as Corporate Controller for Hughes Supply, a Fortune 500, NYSE-listed company that was acquired by Home Depot and became part of HD Supply. In his early career, Mr. Joseph spent six years at PricewaterhouseCoopers as an auditor and strategic financial advisor across a variety of industries.
Wetteny Joseph,自2021年6月起担任Zoetis Inc. 执行副总裁兼首席财务官。Joseph先生从Catalent加入Zoetis Inc. ,在那里他服务了13年,最近一次是在2018年2月至2021年5月担任Catalent的高级副总裁兼首席财务官。Joseph先生于2008年加入Catalent,担任副总裁兼公司财务总监,并担任高级财务职位,直至2015年10月被任命为公司主要业务部门之一的临床供应服务总裁。在加入Catalent之前,Joseph先生在工业分销公司HD Supply担任过各种高级财务职位,包括其管道和暖通空调业务部门的首席财务官。他还曾担任Hughes Supply的公司财务总监,Hughes Supply是财富500强纽约证券交易所上市公司,被Home Depot收购并成为HD Supply的一部分。在他的早期职业生涯中,Joseph先生在普华永道工作了六年,担任多个行业的审计师和战略财务顾问。
Wetteny Joseph,has served as Zoetis Inc. Executive Vice President and Chief Financial Officer since June 2021. Mr. Joseph joined Zoetis from Catalent, where he served for 13 years, most recently as Senior Vice President and Chief Financial Officer of Catalent from February 2018 to May 2021. Mr. Joseph joined Catalent in September 2008 where he served as Corporate Controller until October 2012, then as Vice President Finance across multiple business units until October 2015, when he was named President, Clinical Supply Services, one of the company's principal business units. Before joining Catalent, Mr. Joseph held a variety of senior financial positions at the industrial distribution company HD Supply, including as CFO of its plumbing and HVAC business unit. He also served as Corporate Controller for Hughes Supply, a Fortune 500, NYSE-listed company that was acquired by Home Depot and became part of HD Supply. In his early career, Mr. Joseph spent six years at PricewaterhouseCoopers as an auditor and strategic financial advisor across a variety of industries.
Wafaa Mamilli

Wafaa Mamilli自2020年1月以来一直担任执行副总裁兼首席信息和数字官。Mamilli女士从礼来公司(Eli Lilly and Company)加入Zoetis,最近从2019年1月至2020年1月担任该业务部门的全球首席信息官。 她在全球范围内负责糖尿病患者,肿瘤学,生物医学和国际业务的客户体验,销售,市场营销和医疗事务的数字和技术事务。 在此之前,她在2016年3月至2019年3月担任礼来公司的首席信息安全官,并在2014年5月至2016年3月担任糖尿病业务部和真实世界证据的信息官。在礼来公司任职期间,Mamilli女士担任过各种职务。 在建立高绩效团队的过程中确定国际和美国领导职位,并在医疗保健,信息技术,大数据和分析的交汇处发现机会。


Wafaa Mamilli,has served as Zoetis Inc. Executive Vice President, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health since November 2022. She served as Zoetis Inc. Executive Vice President and Chief Information and Digital Officer from January 2020 to October 2022. Ms. Mamilli joined Zoetis from Eli Lilly and Company where she most recently served as Global Chief Information Officer for business units from January 2019 to January 2020. Prior to that, she was Eli Lilly's Chief Information Security Officer from March 2016 to March 2019 and Information Officer for the Diabetes Business Unit & Real World Evidence from May 2014 to March 2016.
Wafaa Mamilli自2020年1月以来一直担任执行副总裁兼首席信息和数字官。Mamilli女士从礼来公司(Eli Lilly and Company)加入Zoetis,最近从2019年1月至2020年1月担任该业务部门的全球首席信息官。 她在全球范围内负责糖尿病患者,肿瘤学,生物医学和国际业务的客户体验,销售,市场营销和医疗事务的数字和技术事务。 在此之前,她在2016年3月至2019年3月担任礼来公司的首席信息安全官,并在2014年5月至2016年3月担任糖尿病业务部和真实世界证据的信息官。在礼来公司任职期间,Mamilli女士担任过各种职务。 在建立高绩效团队的过程中确定国际和美国领导职位,并在医疗保健,信息技术,大数据和分析的交汇处发现机会。
Wafaa Mamilli,has served as Zoetis Inc. Executive Vice President, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health since November 2022. She served as Zoetis Inc. Executive Vice President and Chief Information and Digital Officer from January 2020 to October 2022. Ms. Mamilli joined Zoetis from Eli Lilly and Company where she most recently served as Global Chief Information Officer for business units from January 2019 to January 2020. Prior to that, she was Eli Lilly's Chief Information Security Officer from March 2016 to March 2019 and Information Officer for the Diabetes Business Unit & Real World Evidence from May 2014 to March 2016.
Jeannette Ferran Astorga

Jeannette Ferran Astorga,自2022年1月起担任执行副总裁、企业事务、通信和首席可持续发展官,并担任ZoETS基金会主席。她于2020年9月加入Zoetis,担任副总裁兼可持续发展负责人。在加入Zoetis之前,Ferran Astorga女士曾担任ascena Retail Group的企业责任副总裁。ascena Retail Group是一家财富500强公司,自2015年以来一直在ascena Retail Group任职,领导着负责供应链合规性和可持续性、多样性和包容性以及企业慈善事业的全球团队。Ferran Astorga女士在安公司(ANN INC.)担任各种管理职务,责任越来越重。安公司是一家在纽约证券交易所上市的女性时尚零售公司,被ascena零售集团收购。


Jeannette Ferran Astorga,has served as Zoetis Inc. Executive Vice President, Corporate Affairs, Communications and Chief Sustainability Officer since January 2022 and also serves as President of the Zoetis Foundation. She joined Zoetis in September 2020 as Vice President, Head of Sustainability. Prior to joining Zoetis, Ms. Ferran Astorga was Vice President of Corporate Responsibility at the Ascena Retail Group where she served since 2015 leading the global team responsible for strategic enterprise initiatives, including supply chain compliance, sustainability, diversity and inclusion, and corporate philanthropy. Ms. Ferran Astorga held a variety of leadership roles with increasing responsibility at ANN INC., a women's fashion retail company that was acquired by Ascena Retail Group.
Jeannette Ferran Astorga,自2022年1月起担任执行副总裁、企业事务、通信和首席可持续发展官,并担任ZoETS基金会主席。她于2020年9月加入Zoetis,担任副总裁兼可持续发展负责人。在加入Zoetis之前,Ferran Astorga女士曾担任ascena Retail Group的企业责任副总裁。ascena Retail Group是一家财富500强公司,自2015年以来一直在ascena Retail Group任职,领导着负责供应链合规性和可持续性、多样性和包容性以及企业慈善事业的全球团队。Ferran Astorga女士在安公司(ANN INC.)担任各种管理职务,责任越来越重。安公司是一家在纽约证券交易所上市的女性时尚零售公司,被ascena零售集团收购。
Jeannette Ferran Astorga,has served as Zoetis Inc. Executive Vice President, Corporate Affairs, Communications and Chief Sustainability Officer since January 2022 and also serves as President of the Zoetis Foundation. She joined Zoetis in September 2020 as Vice President, Head of Sustainability. Prior to joining Zoetis, Ms. Ferran Astorga was Vice President of Corporate Responsibility at the Ascena Retail Group where she served since 2015 leading the global team responsible for strategic enterprise initiatives, including supply chain compliance, sustainability, diversity and inclusion, and corporate philanthropy. Ms. Ferran Astorga held a variety of leadership roles with increasing responsibility at ANN INC., a women's fashion retail company that was acquired by Ascena Retail Group.
Robert J. Polzer

Robert J. Polzer 自2022年1月起担任执行副总裁兼研发总裁。Polzer博士于2015年加入Zoetis,担任全球治疗学主管。在Zoetis之前,Polzer博士在辉瑞公司从事药物代谢研究超过20年,其作用是提高组织影响力,包括在药物动力学、动力学和代谢领域的全球领导地位。


Robert J. Polzer,has served as Zoetis Inc. Executive Vice President and President, Research and Development since January 2022. Dr. Polzer joined Zoetis in 2015 as the Head of Global Therapeutics. Prior to Zoetis, Dr. Polzer spent over 20 years with Pfizer in drug metabolism research with roles of increasing organizational impact including global leadership of Pharmcokinetics, Dynamics, and Metabolism.
Robert J. Polzer 自2022年1月起担任执行副总裁兼研发总裁。Polzer博士于2015年加入Zoetis,担任全球治疗学主管。在Zoetis之前,Polzer博士在辉瑞公司从事药物代谢研究超过20年,其作用是提高组织影响力,包括在药物动力学、动力学和代谢领域的全球领导地位。
Robert J. Polzer,has served as Zoetis Inc. Executive Vice President and President, Research and Development since January 2022. Dr. Polzer joined Zoetis in 2015 as the Head of Global Therapeutics. Prior to Zoetis, Dr. Polzer spent over 20 years with Pfizer in drug metabolism research with roles of increasing organizational impact including global leadership of Pharmcokinetics, Dynamics, and Metabolism.
Nick Ashton

Nick Ashton自2022年5月起担任Zoetis公司执行副总裁兼全球制造和供应总裁。Ashton先生于2020年加入Zoetis,担任全球外部供应主管,领导公司全球外部制造网络的各个方面,监督CMO跟上客户需求。


Nick Ashton,has served as Zoetis Inc. Executive Vice President and President, Global Manufacturing and Supply since May 2022. Mr. Ashton joined Zoetis in 2020 as Head of Global External Supply, where he led all aspects of the company's global external manufacturing network, overseeing CMOs to keep pace with customer demand.
Nick Ashton自2022年5月起担任Zoetis公司执行副总裁兼全球制造和供应总裁。Ashton先生于2020年加入Zoetis,担任全球外部供应主管,领导公司全球外部制造网络的各个方面,监督CMO跟上客户需求。
Nick Ashton,has served as Zoetis Inc. Executive Vice President and President, Global Manufacturing and Supply since May 2022. Mr. Ashton joined Zoetis in 2020 as Head of Global External Supply, where he led all aspects of the company's global external manufacturing network, overseeing CMOs to keep pace with customer demand.
Jamie Brannan

Jamie Brannan自2022年11月起担任Zoetis Inc.执行副总裁兼国际业务和水产养殖总裁。他于2021年6月至2022年11月担任Zoetis公司国际业务总裁。2016年至2021年,他担任Zoetis Inc.英国、爱尔兰和北欧集群高级副总裁。Brannan先生从Molnlycke Health Care加入Zoetis公司,最近担任英国和爱尔兰外科业务总监兼总经理。


Jamie Brannan,has served as Zoetis Inc. Executive Vice President and Group President International Operations, Aquaculture and Global Diagnostics since November 2022. He served as Zoetis Inc. President of International Operations from June 2021 to November 2022. He served as Zoetis Inc. Senior Vice President of the U.K., Ireland and Nordics Cluster from 2016 to 2021. Mr. Brannan joined Zoetis from Mlnlycke Health Care where he most recently served as the Surgical Business Director and General Manager for the U.K. and Ireland.
Jamie Brannan自2022年11月起担任Zoetis Inc.执行副总裁兼国际业务和水产养殖总裁。他于2021年6月至2022年11月担任Zoetis公司国际业务总裁。2016年至2021年,他担任Zoetis Inc.英国、爱尔兰和北欧集群高级副总裁。Brannan先生从Molnlycke Health Care加入Zoetis公司,最近担任英国和爱尔兰外科业务总监兼总经理。
Jamie Brannan,has served as Zoetis Inc. Executive Vice President and Group President International Operations, Aquaculture and Global Diagnostics since November 2022. He served as Zoetis Inc. President of International Operations from June 2021 to November 2022. He served as Zoetis Inc. Senior Vice President of the U.K., Ireland and Nordics Cluster from 2016 to 2021. Mr. Brannan joined Zoetis from Mlnlycke Health Care where he most recently served as the Surgical Business Director and General Manager for the U.K. and Ireland.
Rimma Driscoll

Rimma Driscoll是Zoetis的执行副总裁兼全球战略、商业和业务发展以及全球生物设备主管。在2022年担任Zoetis执行领导团队成员之前,Driscoll女士曾担任高级副总裁兼全球业务发展、业务整合和战略联盟主管(2020年至2022年),以及Zoetis副总裁兼全球业务发展和战略联盟主管(2016年至2020年)。在担任Zoetis的行政领导之前,她从1994年到2016年在Procter & Gamble担任越来越重要的职务。她于2012年至2016年担任欧洲企业全球业务发展执行全球主管期间,在瑞士日内瓦建立并领导公司的全球业务发展集团。除了目前在Zoetis担任的职务外,她还担任Pumpkin Insurance(一家预防性护理和宠物保险提供商,Zoetis持有少数股权)的董事会成员。她持有Bowling Green State University的化学学士学位,以及Xavier University的工商管理硕士学位。


Rimma Driscoll,has served on Dexcom, Inc. Board since August 2023. Ms. Driscoll currently serves as Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices of Zoetis, the world's leading animal health company and a member of the Fortune 500. In this role, Ms. Driscoll oversees the company's global business strategy, the execution of commercial launch plans, external business development (M&A) and integration efforts, and has oversight for Zoetis' Global BioDevices business. She joined Zoetis in 2016 and previously held the titles of Senior Vice President, Business Development from January 2020 to November 2022; and Vice President, Business Development and Commercial Alliances from 2016 to January 2020. Prior to joining Zoetis, Ms. Driscoll spent 21 years at Procter & Gamble where she led global business development and strategic alliances across multiple businesses in pharmaceuticals, consumer healthcare, beauty care, and new business ventures. Ms. Driscoll is a board member of Pumpkin Insurance, a preventive care and pet insurance company. Ms. Driscoll completed her Master of Business Administration from Xavier University, Williams College of Business, and her Bachelor of Science in Chemistry from Bowling Green State University.
Rimma Driscoll是Zoetis的执行副总裁兼全球战略、商业和业务发展以及全球生物设备主管。在2022年担任Zoetis执行领导团队成员之前,Driscoll女士曾担任高级副总裁兼全球业务发展、业务整合和战略联盟主管(2020年至2022年),以及Zoetis副总裁兼全球业务发展和战略联盟主管(2016年至2020年)。在担任Zoetis的行政领导之前,她从1994年到2016年在Procter & Gamble担任越来越重要的职务。她于2012年至2016年担任欧洲企业全球业务发展执行全球主管期间,在瑞士日内瓦建立并领导公司的全球业务发展集团。除了目前在Zoetis担任的职务外,她还担任Pumpkin Insurance(一家预防性护理和宠物保险提供商,Zoetis持有少数股权)的董事会成员。她持有Bowling Green State University的化学学士学位,以及Xavier University的工商管理硕士学位。
Rimma Driscoll,has served on Dexcom, Inc. Board since August 2023. Ms. Driscoll currently serves as Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices of Zoetis, the world's leading animal health company and a member of the Fortune 500. In this role, Ms. Driscoll oversees the company's global business strategy, the execution of commercial launch plans, external business development (M&A) and integration efforts, and has oversight for Zoetis' Global BioDevices business. She joined Zoetis in 2016 and previously held the titles of Senior Vice President, Business Development from January 2020 to November 2022; and Vice President, Business Development and Commercial Alliances from 2016 to January 2020. Prior to joining Zoetis, Ms. Driscoll spent 21 years at Procter & Gamble where she led global business development and strategic alliances across multiple businesses in pharmaceuticals, consumer healthcare, beauty care, and new business ventures. Ms. Driscoll is a board member of Pumpkin Insurance, a preventive care and pet insurance company. Ms. Driscoll completed her Master of Business Administration from Xavier University, Williams College of Business, and her Bachelor of Science in Chemistry from Bowling Green State University.
Ester Banque

Ester Banque,自2023年7月起担任硕腾公司执行副总裁兼美国业务总裁。Banque女士从Bristol-Meyers Squibb(BMS)加入硕腾,最近担任硕腾高级副总裁兼美国血液学和细胞疗法总经理。在此之前,她是高级副总裁兼国际市场主管。在加入BMS之前,Banque女士在诺华工作了25年,在那里她担任过各种职务,责任越来越大。


Ester Banque,has served as Zoetis Inc. Executive Vice President and President, U.S. Operations since July 2023. Ms. Banque joined Zoetis from Bristol-Meyers Squibb (BMS) where she most recently served as Senior Vice President and General Manager of U.S. Hematology and Cell Therapy. Prior to that she was Senior Vice President and Head of International Markets. Before joining BMS, Ms. Banque spent 25 years at Novartis where she held a variety of roles with increasing responsibility.
Ester Banque,自2023年7月起担任硕腾公司执行副总裁兼美国业务总裁。Banque女士从Bristol-Meyers Squibb(BMS)加入硕腾,最近担任硕腾高级副总裁兼美国血液学和细胞疗法总经理。在此之前,她是高级副总裁兼国际市场主管。在加入BMS之前,Banque女士在诺华工作了25年,在那里她担任过各种职务,责任越来越大。
Ester Banque,has served as Zoetis Inc. Executive Vice President and President, U.S. Operations since July 2023. Ms. Banque joined Zoetis from Bristol-Meyers Squibb (BMS) where she most recently served as Senior Vice President and General Manager of U.S. Hematology and Cell Therapy. Prior to that she was Senior Vice President and Head of International Markets. Before joining BMS, Ms. Banque spent 25 years at Novartis where she held a variety of roles with increasing responsibility.
Roxanne Lagano

Roxanne Lagano,自2012年11月起担任Zoetis公司执行副总裁兼首席人力资源官,于2020年1月开始负责全球运营和安保职能。此前,她曾在2015年至2019年期间监督公司的企业传播职能。Lagano女士于1997年加入Pfizer,担任过多个职位,包括Pfizer全球人力资源全球薪酬、福利和健康高级副总裁和业务交易高级总监。


Roxanne Lagano,has served as Zoetis Inc. Executive Vice President and Chief Human Resources Officer since November 2012 and in January 2020 she took on responsibility for Global Operations and Security functions. She previously had oversight of the company's Corporate Communications function from 2015 to 2019. Ms. Lagano joined Pfizer in 1997 and held various positions, including Senior Vice President, Global Compensation, Benefits and Wellness and Senior Director, Business Transactions, Pfizer Worldwide Human Resources.
Roxanne Lagano,自2012年11月起担任Zoetis公司执行副总裁兼首席人力资源官,于2020年1月开始负责全球运营和安保职能。此前,她曾在2015年至2019年期间监督公司的企业传播职能。Lagano女士于1997年加入Pfizer,担任过多个职位,包括Pfizer全球人力资源全球薪酬、福利和健康高级副总裁和业务交易高级总监。
Roxanne Lagano,has served as Zoetis Inc. Executive Vice President and Chief Human Resources Officer since November 2012 and in January 2020 she took on responsibility for Global Operations and Security functions. She previously had oversight of the company's Corporate Communications function from 2015 to 2019. Ms. Lagano joined Pfizer in 1997 and held various positions, including Senior Vice President, Global Compensation, Benefits and Wellness and Senior Director, Business Transactions, Pfizer Worldwide Human Resources.